FDA Delays Decision On Roche Anemia Drug
U.S. regulators have accepted Roche Holding AG's Biologic License Application for its hotly litigated anti-anemia drug Mircera, but will extend their review for another three months to review extra data submitted...To view the full article, register now.
Already a subscriber? Click here to view full article